Expression of estrogen receptor, progesterone receptor, and Her-2/ neu in primary and extra-corporeal endometrial cancer

Histology and Histopathology

Volumn 28, Issue 6, 2013, Pages 787-794

  Tangjitgamol, Siriwan ^a   Tanvanich, Sujitra ^a   Srijaipracharoen, Sunamchok ^a   Manusirivithaya, Sumonmal ^a  

^a NAVAMINDRADHIRAJ UNIVERSITY   (Thailand)

Author keywords

Estrogen receptor; Extra corporeal lesion; Her 2 neu; Primary endometrial cancer; Progesterone receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ARTICLE; CANCER STAGING; COMPARATIVE STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; FEMALE; HUMAN; METABOLISM; METASTASIS; MIDDLE AGED; MULTIPLE CANCER; OVARY TUMOR; PATHOLOGY; UTERINE CERVIX TUMOR;

CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84879000638     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Coronado P.J., Vidart JA. and Lopez-Asenjo J.A. (2001). p53 overexpression predicts endometrial carcinoma recurrent better than HER2/neu overexpression. Eur. J. Obstet. Gynecol. Reprod. Biol. 98, 103-108.
2. Decruze S. B and Green J.A. (2007). Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int. J. Gynecol. Cancer 17, 964-978.
3. Engelsen I.B., Stefansson I.M., Beroukhim R., Sellers W.R., Meyerson M., Akslen L.A. and Salvesen H.B. (2008). Her-2/neu expression is associated with high tumor cell proliferation and aggression phenotype in population based patient series of endometrial carcinomas. Int. J. Oncol. 32, 307-316.
4. Fukuda K., Mori M., Uchiyama M., Iwai K., Iwasaka T. and Sugimori H. (1998). Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Gynecol. Oncol. 69, 220-225.
5. Jemal A., Bray F., Center M.M., Ferlay J., Ward E. and Forman D. (2011). Global Cancer Statistics. CA. Cancer. J. Clin. 61, 1-22.
6. Jeon Y.T., Park I.A., Kim Y.B., Kim J.W., Park N.H., Kang S.B., Lee H.P. and Song Y.S. (2006). Steroid receptor expressions in endometrial cancer: Clinical significance and epidemiological implication. Cancer Lett. 239, 198-204.
7. Ma B.B., Oza A., Eisenhauer E., Stanimir G., Carey M., Chapman W., Latta E., Sidhu K., Powers J., Walsh W. and Fyles A. (2004). The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group. Int. J. Gynecol. Cancer 14, 650-658.
8. Niederacher D., An H.X., Cho Y.J., Hantschmann P., Bender H.G. and Beckmann M.W. (1999). Mutations and amplification of oncogenes in endometrial cancer. Oncology 56, 59-65.
9. Runowicz C.D., Nuchtern L.M., Braunstein J.D. and Jones J.G. (1990). Heterogeneity in hormone receptor status in primary and metastatic endometrial cancer. Gynecol. Oncol. 38, 437-441.
10. Saffari B., Jones L.A., El-Naggar A., Felix J.C., George J. and Press M.F. (1995). Amplification and overexpression of HER-2/neu (cerbB2) in endometrial cancer: correlation with overall survival. Cancer. Res. 55, 5693-5698.
11. Singh M., Zaino R.J., Filiaci V.J. and Leslie K.K. (2007). Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 106, 325-333.
12. Srijaipracharoen S., Tangjitgamol S., Tanvanich S., Manusirivithaya S., Khunnarong J., Thavaramara T., Leelahakorn S. and Pataradool K. (2010). Expression of ER, PR, and Her-2/neu in endometrial cancer: a clinicopathological study. Asian. Pac. J. Cancer. Prev. 11, 215-220.
13. Suthipintawong C., Wejaranayang C. and Vipupinyo C. (2008). Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma. J. Med. Assoc. Thai. 91, 1779-1784.
14. Thigpen J.T., Brady M.F., Alvarez R.D., Adelson M.D., Homesley H.D., Manetta A., Soper J.T. and Given F.T. (1999). Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J. Clin. Oncol. 17, 1736-1744.
15. Vandenput I., Trovik J., Leunen K., Wik E., Stefansson I., Akslen L., Moerman P., Vergote I., Salvesen H. and Amant F. (2011). Evolution in endometrial cancer: evidence from an immunohistochemical study. Int. J. Gynecol. Cancer. 21, 316-322.